LONDON, Sept. 24, 2017 /PRNewswire/ -- Edwards
Lifesciences Corporation (NYSE: EW), the global leader in
patient-focused innovations for structural heart disease and
critical care monitoring, today announced key events for the
company during the PCR London Valves 2017 course, as the meeting
celebrates 15 years of transcatheter aortic valve replacement.
Among the scheduled events and data presentations are:
- Introduction of the Edwards SAPIEN 3 Ultra System –
Edwards' CE Mark-pending system for transcatheter aortic valve
replacement includes the new SAPIEN 3 Ultra valve, which adds a
taller outer skirt to the proven SAPIEN 3 valve design. Initially
incorporated with valve sizes 20, 23 and 26 mm, this new feature is
designed to further improve the SAPIEN 3 valve's best-in-class
outcomes. The valve is offered with the SAPIEN 3 Ultra delivery
system, which introduces an "on balloon" design, removing the need
for valve alignment during the procedure, and is compatible with
the new 14F Axela expandable sheath. The Edwards SAPIEN 3 Ultra
System is expected to receive CE Mark by the end of the year, and
the company also has plans to introduce this system in the United States late in 2018.
- 6-month outcomes with the Edwards CENTERA Transcatheter
Heart Valve System – On Monday, Sept.
25, in the Late-Breaking TAVI Trials session, new results of
the self-expanding Edwards CENTERA valve will be discussed. Results
presented earlier this year on the 30-day outcomes with the CENTERA
valve demonstrated a very high survival rate, a low disabling
stroke rate and a low percent permanent pacemaker rate. In
addition, there was a low rate of moderate paravalvular leak among
patients, and no severe paravalvular leak reported at 30 days after
transcatheter valve replacement. The Edwards CENTERA valve is
repositionable and retrievable and can be delivered through a
low-profile 14-French delivery system that features a motorized
handle that results in stable valve deployment. The valve is
uniquely packaged – fully pre-attached, which facilitates simple
and rapid device preparation.
- Symposium: Transcatheter heart valve therapies for all heart
valves: from an innovation strategy to mainstream therapy –
This sponsored session on Sunday, Sept.
24, is intended to review the latest clinical trials
involving Edwards' aortic, mitral, tricuspid and pulmonary valve
therapies.
- Symposium: Edwards Cardioband Transcatheter Valve Repair
System: expanding options for patients – This sponsored session
on Tuesday, Sept. 26, is focused on
the current experience and clinical results of the Edwards
Cardioband system and a discussion of Edwards' innovations for
transcatheter valve therapies.
"As PCR London Valves celebrates 15 years of transcatheter
aortic valve replacement, Edwards is proud to have led the
development and evolution of TAVR as a preferred therapy for
patients in need around the world," said Larry L. Wood, Edwards' corporate vice
president, transcatheter heart valves.
The Edwards SAPIEN 3 Ultra System and CENTERA Transcatheter
Heart Valve System are not currently available for commercial sale
in any country.
About Edwards Lifesciences
Edwards Lifesciences, based
in Irvine, Calif., is the global
leader in patient-focused medical innovations for structural heart
disease, as well as critical care and surgical monitoring. Driven
by a passion to help patients, the company collaborates with the
world's leading clinicians and researchers to address unmet
healthcare needs, working to improve patient outcomes and enhance
lives. For more information, visit www.Edwards.com and follow us on
Twitter @EdwardsLifesci.
This news release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These forward-looking
statements include, but are not limited to, statements regarding
expected future product approvals, dates of commercial availability
and expected benefits and results. Forward-looking statements are
based on estimates and assumptions made by management of the
company and are believed to be reasonable, though they are
inherently uncertain and difficult to predict. Our forward-looking
statements speak only as of the date on which they are made and we
do not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of the
statement.
Forward-looking statements involve risks and uncertainties that
could cause results to differ materially from those expressed or
implied by the forward-looking statements based on a number of
factors, including but not limited to, unexpected outcomes after
longer term clinical experience with the product; or unanticipated
quality, manufacturing or regulatory delays or issues. These
factors are detailed in the company's filings with the Securities
and Exchange Commission including its Annual Report on Form 10-K
for the year ended December 31, 2016.
These filings, along with important safety information about our
products, may be found at edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, Axela,
Cardioband, CENTERA, Edwards SAPIEN, Edwards SAPIEN 3, Edwards
SAPIEN 3 Ultra, SAPIEN, SAPIEN 3, and SAPIEN 3 Ultra are trademarks
of Edwards Lifesciences Corporation. All other trademarks are the
property of their respective owners.
View original content with
multimedia:http://www.prnewswire.com/news-releases/edwards-announces-key-events-for-pcr-london-valves-2017-300524703.html
SOURCE Edwards Lifesciences Corporation